ReviewCell metabolism2015
Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology.
Review in Cell metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Melatonin levels in the Alzheimer's disease continuum: a systematic review.Alzheimer's research & therapy · 2021Pooled it
- Pooled it
- Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Pooled it
- Cognitive Effects of Adding Caloric Restriction to Aerobic Exercise Training in Older Adults with Obesity.Obesity (Silver Spring, Md.) · 2019Trial
- Different hypothalamic regions in late-onset Alzheimer's disease and aging: involvement and links with cognitive and non-cognitive features.GeroScience · 2026Article
- Hypothalamus Amyloid Levels Are Associated with Early Sex-Dependent Alterations in Peripheral Energy Homeostasis in TgF344-AD Rats.Molecular neurobiology · 2026Article
- Tanycytes: bloodhounds of the metabolic brain.Trends in endocrinology and metabolism: TEM · 2026Review
- Diagnosis and Prediction of Alzheimer's Disease via a High-Level Convolutional Block Attention Module-Residual Network.Interdisciplinary sciences, computational life sciences · 2026Article
- Metabolic Brain Disorders: Prodromes, Symptoms, and Syndromes.International journal of molecular sciences · 2026Review
- A Case Series on Longitudinal Hypothalamic Morphology in Mild Cognitive Impairment.Annals of geriatric medicine and research · 2026Article
- Tanycytic degeneration impairs tau clearance and contributes to Alzheimer's disease pathology.Cell press blue · 2026Article
- Cellular signatures of melanocortin pathway genes across the locus coeruleus.Acta neuropathologica communications · 2026Article
- Alzheimer's Pathology Enhances Excitatory Synaptic Input and Integration in VTA Dopamine Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026Article
- Brain Nutrient Sensing: A Unifying Framework.Annual review of physiology · 2026Review
- Is Hypothalamic Dysfunction a Cause of Type II Diabetes Mellitus?Neuroendocrinology · 2026Review
- Associations of novel visceral obesity indices (METS-VF and BRI) with dementia: the role of metabolic mediators and genetic susceptibility.Frontiers in nutrition · 2026Article
- The Role of Supraoptic Hypothalamic Arginine Vasopressin Neurons in Aging-Associated Water Balance and Thermoregulatory Deficits.bioRxiv : the preprint server for biology · 2025Article
- PKC-dependent enhancement of glutamate input to VTA dopamine neurons in 3xTg-AD mice.bioRxiv : the preprint server for biology · 2025Article
- Early onset of hyperexcitability of medial mammillary body neurons in 5XFADJournal of neurophysiology · 2025Article
- Vulnerability of mitochondrial OXPHOS complexes in the arcuate nucleus of the hypothalamus of Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2025Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Alzheimer's disease (AD) is increasingly recognized as a complex neurodegenerative disease beginning decades prior to the cognitive decline. While cognitive deficits remain the cardinal manifestation of AD, metabolic and non-cognitive abnormalities, such as alterations in body weight and neuroendocrine functions, are also present, often preceding the cognitive decline. Furthermore, hypothalamic dysfunction can also be a driver of AD pathology. Here we offer a brief appraisal of hypothalamic dysfunction in AD and provide insight into an underappreciated dual role of the hypothalamus as both a culprit and target of AD pathology, as well as into new opportunities for therapeutic interventions and biomarker development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.